On-label (postmenopausal women, breast cancer): Most-reported subjective effects are joint pain / arthralgia / stiffness (~30-40%), hot flushes (~30%), fatigue, vaginal dryness. The arthralgia is severe enough that ~10-15% of women discontinue therapy because of it. Bone density loss is silent until a fracture — that's the surveillance issue.

Off-label (men on TRT / AAS managing high E2):

• Onset of E2 reduction: Detectable within 24-48 hours; bloodwork shifts visible within 4-7 days at steady state
• Subjective signs of appropriate dosing: resolution of nipple sensitivity, less water retention, clearer mood, reduced bloat, sometimes improved libido (when high-E2 was suppressing it)
• Subjective signs of overdosing / E2 crash:
  • Joint pain — particularly knees, hands, hips — characteristic "dry joint" feeling, can develop within days of an over-shot dose
  • Libido collapse / erectile dysfunction — often reported as "sudden loss of any sexual interest, can't even initiate"
  • Mood crash — anhedonia, irritability, anxiety, low motivation — can mimic depression
  • Fatigue + brain fog — distinct from high-E2 fatigue (which feels "wet/bloated"), low-E2 fatigue feels "drained/empty"
  • Lipid disruption — LDL up, HDL down, triglycerides up over weeks
  • Bone density loss — silent, only detectable on DEXA over months
  • Gum / oral tissue dryness, mucosal dryness — early subtle sign in some users
  • Increased acne / dry skin combo — paradoxical; T:E2 ratio shifts androgenic
• Recovery from E2 crash: stop AI, E2 typically rebounds over 1-2 weeks (since aromatase activity returns as drug clears, half-life ~50h). Joint pain and libido often the first to recover; mood and lipids slower.

The Dylan-relevant takeaway: Anastrozole has a narrow therapeutic window in men. The dose that "works" for high-E2 management can cross into "crashing E2" with shifts of 0.25-0.5 mg per week. This is why TRT clinics dose by E2 bloodwork, not by symptoms alone. For a young eugonadal male with no high-E2 problem to solve, the drug has only the downside risk and no upside.

• Tolerance buildup: Minimal pharmacological tolerance to aromatase inhibition over months-to-years of use. Aromatase activity returns to baseline within ~7-14 days of discontinuation as drug clears.
• Recommended cycle: N/A in approved indication (continuous). In male off-label use, "as needed" pulsed dosing is standard — only on cycle for AAS users; only when E2 elevated for TRT users.
• Reset protocol: No rebound, no withdrawal — drug clearance allows aromatase to resume function smoothly. E2 typically returns to pre-AI levels over 1-2 weeks.
• Long-term tolerance / chronic-use concerns: Years-long continuous use produces cumulative bone density loss and lipid changes. Periodic dose reduction or AI holiday (in TRT contexts where sustainable) is sometimes attempted but not RCT-validated.

Synergistic with (clinical contexts)

• Calcium + Vitamin D3 + K2 + bisphosphonates: Bone protection during chronic AI use is standard of care for postmenopausal breast cancer — bisphosphonates (zoledronate, alendronate) or denosumab routinely added when DEXA shows BMD decline. Dylan's V4 D3+K2 would be relevant only if AI ever indicated.
• TRT (testosterone cypionate / enanthate): AI is added when TRT-induced E2 climbs symptomatically. Standard TRT-clinic stack — but the combination is managed, not a casual add-on.
• HCG (during AAS cycle): Sometimes co-administered to maintain testicular function; the AI manages aromatization while HCG keeps Leydig cells active.

Avoid stacking with

• SERMs (tamoxifen, raloxifene, enclomiphene, clomiphene) without clinical supervision: Combined ER blockade + aromatase blockade can crash tissue-level E2 to severe-deficiency phenotype. Joint pain, bone loss, lipid disruption, mood crash compound.
• Other aromatase inhibitors (letrozole, exemestane): Redundant; never indicated. Letrozole at 2.5 mg + anastrozole 1 mg is irrational over-dosing.
• GnRH agonists (leuprolide) without specific protocol: Used together only in specific oncology/endocrine contexts; otherwise additive HPG suppression.
• Estrogen replacement therapy: Mechanistic conflict — defeats purpose of the AI.
• Heavy alcohol use: Hepatic burden + lipid changes compound; also alcohol independently increases aromatase activity (so high alcohol intake confounds dose-response).
• Phytoestrogen-heavy diets (very high soy, flax) during AI use: Mostly clinically minor but worth flagging for completeness.

Neutral / safe co-administration

• Most non-hormonal nootropics in Dylan's V4/V5 stack: Modafinil, citicoline, NAC, magnesium, fish oil, theanine, rhodiola, curcumin, beta-alanine, creatine — no PD/PK conflict
• Caffeine: No interaction
• Bromantane, Adamax/Semax, Selank: No PK conflict; PD non-overlapping
• Most cardiovascular meds: No major interactions; LFT and lipid monitoring with chronic use covers theoretical concerns

CYP enzymes affected by anastrozole: Modest in vitro inhibition of CYP1A2, CYP2C8/9, CYP3A4 — but at clinically relevant doses, no significant effect on substrates of these enzymes. Anastrozole itself is metabolized by N-dealkylation (non-CYP) and minor CYP3A4 — not a major DDI driver in either direction.

• CYP19A1 (aromatase) polymorphisms: Variants modulate baseline aromatase activity and may affect both endogenous E2 levels and anastrozole response magnitude. Relevant for breast cancer pharmacogenomics research; not yet clinical-grade dosing guidance. Dylan's 23andMe (~June 2026) may report some CYP19A1 calls.
• CYP3A4 / CYP3A5 polymorphisms: Minor metabolic role; not clinically dose-determining for anastrozole.
• ESR1, ESR2 (estrogen receptors): Variants affect tissue response to declining E2 — i.e., who develops worse arthralgia, who has steeper bone loss, who has worse mood effects. Active research area; not clinically applied yet.
• UGT enzymes (glucuronidation): Minor role in anastrozole metabolism; polymorphisms not clinically dose-determining.
• Practical note for Dylan: None applicable — he's not using anastrozole. If ever indicated, his 23andMe results would be informational background, not deterministic.

For Dylan: sourcing is trivially easy if ever indicated. Anastrozole is one of the cheapest gray-market and generic Rx items in the male-hormone-modulator space. The blocker is indication, not access.

Baseline

• Estradiol (sensitive E2 assay, LC-MS/MS preferred — NOT standard immunoassay) — critical; standard assays give inflated/inaccurate values in male range
• Total T, free T, SHBG, LH, FSH — full HPG panel (Dylan: gets this June 2026 anyway)
• Lipid panel (LDL, HDL, triglycerides) — baseline before AI-induced changes
• CMP (LFTs, kidney function) — baseline
• CBC — baseline
• DEXA BMD — if chronic use anticipated, particularly in older or bone-risk users
• 25(OH)D, calcium, magnesium — bone-health support baseline
• Symptom inventory — joint pain baseline, libido baseline, mood baseline (so changes are detectable)

During use

• E2 (sensitive assay) at 4 weeks, 12 weeks, then every 3-6 months — primary dose-titration biomarker; target 20-40 pg/mL for TRT-adjunct context
• Total T, free T at 4-12 weeks — confirms not over-correcting
• Lipid panel at 12 weeks then annually — LDL/HDL drift surveillance
• LFTs at 12 weeks then annually — hepatotoxicity surveillance
• CBC at 12 weeks
• DEXA at 12 months for chronic use — bone density surveillance
• Symptom diary — joint pain, libido, mood, energy, sleep, dryness signs

Post-discontinuation

• E2, T at 4 weeks post-stop — confirm rebound to baseline
• Lipid panel at 12 weeks post-stop — confirm normalization